In a bombshell comparable to the recent belated revelation of the disaster that hormone replacement therapy has been, I have learned that Paxil manufacturer Glaxo-Smith-Kline (GSK) has secretly settled its appeal of the ruling in the Paxil trial last year.
GSK was sued in federal district court in Cheyenne by family members of Donald Schell, the Gillette, Wyoming man who killed his wife, daughter, granddaughter and then himself on February 13, 1998 after two days on the pharmaceutical giants anti-anxiety/depression drug Paxil. The plaintiffs position was that Paxil was the primary cause of Donald Schells actions in the murder-suicide. The jury agreed and the judge in the trial rejected GSKs challenge of the validity of the scientific data presented to the jury by the plaintiffs. As a public service I will be publishing the crucial expert testimony and cross examination of British psychiatrist and psychiatric historian David Healy soon.
GSK appealed the verdict in the case in Denver, but recently gave up, I have been told by Healy. The deal in the appeal settlement GSK made with the plaintiffs calls for the company getting all of its documents back, and a set of confidentiality statements from the plaintiffs side to not release anymore details of the case not already in the public domain. This is an important development in the history of psychiatric medicine. The jury verdict forced GSK to cave in to the demands of the Medicines Control Agency, the British government agency that regulates prescription drugs, that it place a suicide warning on Paxil. GSK has had to place a suicide warning on Paxil in Britain for about a year now. Now the question remains will this same warning ever make it over to this side of the Atlantic, with as much publicity as the hormone replacement story has gotten? Not likely, I believe, but I hope I am wrong.
Even though there isnt a widely publicized suicide warning being given for Paxil, or any other drug in its class, known as Selective Serotonin Reuptake Inhibitors, or SSRIs, its not like there is a complete information black out about these newer generation psychiatric drugs in consumer prescription drug guides.
For example, in the recently published 10th edition of The Pill Book, it warns patients taking SSRIs (i.e. Celexa, Luvox, Paxil, Prozac and Zoloft) that The possibility of suicide exists in severely depressed patients and may be present until the condition is significantly improved. Severely depressed people should be allowed to carry only small quantities of SSRIs to limit the risk of overdose. The term overdose can just as easily be read as killing themselves. Also, As many as 1/3 of people taking an SSRI experience anxiety, sleeplessness and nervousness. In other words all the symptoms that can push a depressed person over the edge and into a suicide attempt. Finally, the recently published 5th edition of The Physicians Desk Reference Pocket Guide to Prescription Drugs warns patients considering taking the SSRI known as Zoloft May also cause mental or emotional symptoms such as: Abnormal dreams or thoughts, aggressiveness, exaggerated feeling well-being, depersonalization (unreal feeling), hallucinations, impaired concentration, memory loss, paranoia, rapid mood shifts, SUICIDAL THOUGHTS, tooth-grinding, WORSENED DEPRESSION (emphasis is the authors).
Now why on Earth are pharmaceutical companies allowed to get away with marketing these drugs as anti-depressants, or anti-anxiety agents when they can produce in patients exactly what they are supposed to treat at such high rates? This is the deeper question about the mass marketing of these drugs the mass media is simply avoiding by a combination of cowardice, laziness and just outright ignorance in reporting on these issues.
Rick Giombetti is a freelance writer who. lives in Seattle. Visit his website at: http://rjgiombetti.blogspot.com/. He can be reached at: firstname.lastname@example.org